Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia

Efrosyni Apostolidou, Jorge Cortes, Apostolia Tsimberidou, Elihu Estey, Hagop Kantarjian, Francis J. Giles

Research output: Contribution to journalArticle

Abstract

Multi-drug resistance (MDR) protein expression is associated with reduced gemtuzumab ozogamicin (Mylotarg) activity. Both cyclosporine-A (CSA) and liposome-encapsulated daunorubicin, DaunoXome (DNX) may reduce the negative impact of MDR. A gemtuzumab ozogamicin, DNX, cytarabine (ara-C) and CSA (MDAC) regimen was piloted in patients with refractory acute myelogenous leukemia (AML) (relapsed 10, primary refractory 1) (median age 37 years (16-67)). One (9%) patient achieved a transient CR, one CRp. Grade 3/4 toxicities included sepsis (seven patients; 63%); hyperbilirubinemia (six patients; 54%), with transaminitis in one patient; mucositis (three patients; 27%). The inclusion of CSA in a gemtuzumab ozogamicin-containing regimen is feasible. The MDAC regimen was associated with significant toxicity in a cohort of patients with very advanced AML.

Original languageEnglish (US)
Pages (from-to)887-891
Number of pages5
JournalLeukemia Research
Volume27
Issue number10
DOIs
StatePublished - Oct 1 2003
Externally publishedYes

Fingerprint

Daunorubicin
Cytarabine
Acute Myeloid Leukemia
Cyclosporine
Multiple Drug Resistance
Mucositis
Hyperbilirubinemia
gemtuzumab
Liposomes
Sepsis

Keywords

  • Acute myeloid leukemia
  • Cyclosporine-A
  • Cytarabine
  • DaunoXome
  • Gemtuzumab ozogamicin
  • MDR
  • Multi-drug resistance
  • Refractory

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. / Apostolidou, Efrosyni; Cortes, Jorge; Tsimberidou, Apostolia; Estey, Elihu; Kantarjian, Hagop; Giles, Francis J.

In: Leukemia Research, Vol. 27, No. 10, 01.10.2003, p. 887-891.

Research output: Contribution to journalArticle

Apostolidou, Efrosyni ; Cortes, Jorge ; Tsimberidou, Apostolia ; Estey, Elihu ; Kantarjian, Hagop ; Giles, Francis J. / Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. In: Leukemia Research. 2003 ; Vol. 27, No. 10. pp. 887-891.
@article{ba80dd1dc02e42299b078324fab09ce5,
title = "Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia",
abstract = "Multi-drug resistance (MDR) protein expression is associated with reduced gemtuzumab ozogamicin (Mylotarg) activity. Both cyclosporine-A (CSA) and liposome-encapsulated daunorubicin, DaunoXome (DNX) may reduce the negative impact of MDR. A gemtuzumab ozogamicin, DNX, cytarabine (ara-C) and CSA (MDAC) regimen was piloted in patients with refractory acute myelogenous leukemia (AML) (relapsed 10, primary refractory 1) (median age 37 years (16-67)). One (9{\%}) patient achieved a transient CR, one CRp. Grade 3/4 toxicities included sepsis (seven patients; 63{\%}); hyperbilirubinemia (six patients; 54{\%}), with transaminitis in one patient; mucositis (three patients; 27{\%}). The inclusion of CSA in a gemtuzumab ozogamicin-containing regimen is feasible. The MDAC regimen was associated with significant toxicity in a cohort of patients with very advanced AML.",
keywords = "Acute myeloid leukemia, Cyclosporine-A, Cytarabine, DaunoXome, Gemtuzumab ozogamicin, MDR, Multi-drug resistance, Refractory",
author = "Efrosyni Apostolidou and Jorge Cortes and Apostolia Tsimberidou and Elihu Estey and Hagop Kantarjian and Giles, {Francis J.}",
year = "2003",
month = "10",
day = "1",
doi = "10.1016/S0145-2126(03)00021-3",
language = "English (US)",
volume = "27",
pages = "887--891",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia

AU - Apostolidou, Efrosyni

AU - Cortes, Jorge

AU - Tsimberidou, Apostolia

AU - Estey, Elihu

AU - Kantarjian, Hagop

AU - Giles, Francis J.

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Multi-drug resistance (MDR) protein expression is associated with reduced gemtuzumab ozogamicin (Mylotarg) activity. Both cyclosporine-A (CSA) and liposome-encapsulated daunorubicin, DaunoXome (DNX) may reduce the negative impact of MDR. A gemtuzumab ozogamicin, DNX, cytarabine (ara-C) and CSA (MDAC) regimen was piloted in patients with refractory acute myelogenous leukemia (AML) (relapsed 10, primary refractory 1) (median age 37 years (16-67)). One (9%) patient achieved a transient CR, one CRp. Grade 3/4 toxicities included sepsis (seven patients; 63%); hyperbilirubinemia (six patients; 54%), with transaminitis in one patient; mucositis (three patients; 27%). The inclusion of CSA in a gemtuzumab ozogamicin-containing regimen is feasible. The MDAC regimen was associated with significant toxicity in a cohort of patients with very advanced AML.

AB - Multi-drug resistance (MDR) protein expression is associated with reduced gemtuzumab ozogamicin (Mylotarg) activity. Both cyclosporine-A (CSA) and liposome-encapsulated daunorubicin, DaunoXome (DNX) may reduce the negative impact of MDR. A gemtuzumab ozogamicin, DNX, cytarabine (ara-C) and CSA (MDAC) regimen was piloted in patients with refractory acute myelogenous leukemia (AML) (relapsed 10, primary refractory 1) (median age 37 years (16-67)). One (9%) patient achieved a transient CR, one CRp. Grade 3/4 toxicities included sepsis (seven patients; 63%); hyperbilirubinemia (six patients; 54%), with transaminitis in one patient; mucositis (three patients; 27%). The inclusion of CSA in a gemtuzumab ozogamicin-containing regimen is feasible. The MDAC regimen was associated with significant toxicity in a cohort of patients with very advanced AML.

KW - Acute myeloid leukemia

KW - Cyclosporine-A

KW - Cytarabine

KW - DaunoXome

KW - Gemtuzumab ozogamicin

KW - MDR

KW - Multi-drug resistance

KW - Refractory

UR - http://www.scopus.com/inward/record.url?scp=0038015273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038015273&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(03)00021-3

DO - 10.1016/S0145-2126(03)00021-3

M3 - Article

C2 - 12860007

AN - SCOPUS:0038015273

VL - 27

SP - 887

EP - 891

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 10

ER -